Precision Medicine Podcast

Follow Precision Medicine Podcast
Share on
Copy link to clipboard

Welcome to the Precision Medicine Podcast, where experts come to discuss the problems oncologists, reference labs, and payers face as precision medicine grows, and consider solutions for advancing the quality of patient-centered cancer care.

Trapelo by Intervention Insights


    • May 21, 2025 LATEST EPISODE
    • monthly NEW EPISODES
    • 34m AVG DURATION
    • 69 EPISODES


    Search for episodes from Precision Medicine Podcast with a specific topic:

    Latest episodes from Precision Medicine Podcast

    Inherited Cancer Risk: What Every Patient and Clinician Needs to Know with Guest Ellen Matloff

    Play Episode Listen Later May 21, 2025 44:31


    When patients understand their inherited risk for cancer, they're empowered to take action—often before cancer has a chance to take hold.In this second episode of our Bringing Precision Medicine to Every Patient series, host Karan Cushman is joined by two trusted experts, Ellen Matloff and Dr. Angella Charnot-Katsikas. Together, they provide clear, practical guidance on how patients and clinicians can identify inherited cancer risk early—and take steps to address it.Whether you're a patient wondering where to begin, or a provider navigating limited time and resources, this episode delivers clear takeaways to help you move from uncertainty to informed action.It's a timely reminder that precision medicine doesn't begin with treatment—it begins with knowledge. And with the right tools and support, patients can take control of their health and rewrite the story for generations to come.Ellen Matloff is a nationally recognized genetic counselor, founder and CEO of My Gene Counsel, and a leading voice in digital health and patient-centered genomics. She founded and led the Yale Cancer Genetic Counseling Program and was a plaintiff in the landmark Supreme Court case that overturned gene patenting.Dr. Angella Charnot-Katsikas is Chief Medical Officer at Palmetto GBA and a molecular diagnostics expert who helps guide coverage decisions through her work in precision medicine policy.They share compelling stories that bring the science to life. Ellen reflects on one of her first BRCA1-positive patients—a healthy young mother who chose preventive surgery based on a powerful family history of cancer and a determination to break the cycle. Dr. Katsikas offers her own experience as both a pre-vivor and survivor, whose early diagnosis was only possible because of proactive testing and screening guided by her family history.The episode also explains why many patients still miss these opportunities—due to limited awareness, inconsistent risk assessments, and systemic barriers in access. The guests highlight the limitations of consumer tests like 23andMe and the critical role of genetic counselors in interpreting results and guiding decisions.They offer actionable strategies for integrating family history collection and risk assessment into routine care, including the use of digital tools in busy or resource-limited settings. Reimbursement challenges are discussed, alongside encouraging progress toward making precision medicine standard of care.Special thanks to our good friend Dr. Kashyap Patel and the No One Left Alone initiative forcollaborating with us on this series. Our goal with Bringing Precision Medicine to Everyone is to equip patients, caregivers and care teams with the knowledge and tools needed to deliver the best of modern cancer care–no matter where a patient lives.

    New Series: Bringing Precision Medicine to Everyone

    Play Episode Listen Later Apr 24, 2025 34:12


    In Episode 66 of the Precision Medicine Podcast, host Karan Cushman kicks off a vital new series, Bringing Precision Medicine to Every Patient, in collaboration with Dr. Kashyap Patel, a nationally respected community oncologist and founder of the No One Left Alone initiative. This series explores what it takes to close the gap between innovation and access in precision cancer care—especially in community and rural settings where disparities remain greatest. Dr. Patel, a long-time advocate for equitable oncology care, shares the real-world barriers patients face—from gaps in provider awareness to financial constraints and restrictive payer policies—and how his organization is actively working to address them. He also offers powerful patient stories that highlight the life-saving potential of timely biomarker testing and personalized therapies.Joining the conversation is Dr. Angella Charnot-Katsikas, a molecular pathologist, policy leader at Palmetto GBA, and breast cancer survivor, who brings a unique perspective from both the clinical and payer sides. She emphasizes the importance of collaboration across care teams, the need for rapid diagnostic turnaround, and the urgency of keeping pace with evolving clinical guidelines.Together, the guests affirm that precision medicine is the standard of care—but for too many, it's still not the reality. This episode lays the foundation for a transformative series focused on dismantling systemic barriers and ensuring every patient—regardless of their zip code—can benefit from the best of modern cancer care.

    How AI is Revolutionizing Precision Medicine: Dr. Douglas Flora & Dr. Sanjay Juneja on the Future of Cancer Care

    Play Episode Listen Later Feb 26, 2025 50:02


    In this episode of the Precision Medicine Podcast, host Karan Cushman engages in a thought-provoking discussion with two pioneers in AI-driven oncology: Dr. Douglas Flora and Dr. Sanjay Juneja. Together, they explore how AI is revolutionizing cancer care, from earlier detection and faster diagnoses to personalized treatments and clinical trial optimization.AI's potential in oncology is game-changing. Dr. Flora and Dr. Juneja break down how AI is helping to identify cancer at its earliest, most treatable stages, automate biomarker testing, and streamline clinical trials to match patients with the best therapies faster than ever before. AI is not just a futuristic concept—it is already helping oncologists reduce misdiagnoses, improve screening accuracy, and speed up treatment approvals, all of which could significantly improve patient outcomes.But if AI is so transformative, why isn't it more widely used? Adoption remains one of the biggest hurdles, with challenges ranging from regulatory barriers and insurance limitations to the slow integration of AI into clinical practice. Karan challenges her guests to explain what needs to change for AI-driven precision medicine to reach more patients—sooner rather than later.With her patient-first perspective, Karan ensures the conversation stays focused on what these advancements mean for real people. Looking ahead to 2030, the discussion explores what a fully AI-integrated oncology system could look like—and why the revolution in cancer care isn't coming—it's already here.Dr. Douglas Flora is the Executive Medical Director of Oncology Services at St. Elizabeth Healthcare, and Dr. Sanjay Juneja is a hematologist-oncologist, social media educator, and VP of Clinical AI Operations at Tempus AI. Both guests are co-founders of Tensor Black, an education and consulting company specializing in AI applications in oncology.

    Advancing Prostate Cancer Care with Dr. William Oh: Precision Medicine, Diagnostics and Advocacy (Part 2)

    Play Episode Listen Later Dec 30, 2024 32:41


    In this two-part episode of the Precision Medicine Podcast, host Karan Cushman continues her deep dive into prostate cancer care with expert guest Dr. William Oh, a leading genitourinary oncologist, Director of Precision Medicine at Yale Cancer Center and Chair of the American Cancer Society National Prostate Cancer Roundtable. Building on part one (episode 63), they explore the transformative role of precision medicine, advanced diagnostics, and targeted therapies—emphasizing the urgent need for greater awareness, understanding, and advocacy as prostate cancer continues to rise steadily. Karan opens the conversation by emphasizing the growing complexity of prostate cancer diagnostics and treatment. Dr. Oh discusses the wide array of diagnostic tools, from PSA tests and MRIs to the cutting-edge PSMA PET scan, which has revolutionized staging and treatment planning by providing detailed insights into cancer spread. He highlights how these tools are helping oncologists tailor treatment plans with unprecedented precision. The discussion shifts to molecular diagnostics, a burgeoning field that provides critical information about the aggressiveness of cancer. Dr. Oh explains how molecular tests, such as genomic profiling, are enabling personalized treatment decisions for prostate cancer patients, particularly those on the fence about options like surgery, radiation, or active surveillance. Karan and Dr. Oh also address disparities in access to these advanced diagnostics, underlining the need for wider implementation. Karan steers the conversation toward advancements in targeted therapies. Dr. Oh outlines breakthroughs in precision treatments, including PARP inhibitors for patients with BRCA mutations and the innovative LU-177-PSMA therapy, a “smart bomb” approach that targets cancer cells with remarkable specificity. He also explores the promise of immunotherapy, though he acknowledges its limited applicability for prostate cancer due to the disease's low mutational burden. The role of artificial intelligence in precision oncology is another key topic. Dr. Oh and Karan discuss how AI and machine learning are helping clinicians process complex data, from imaging to genomic profiles, to guide more informed treatment decisions. Dr. Oh envisions AI as an essential tool for streamlining oncology workflows while preserving the human connection between doctors and patients. Karan highlights the importance of effective communication in prostate cancer care, referencing a recent editorial co-authored by Dr. Oh. Together, they explore the need for more patient-centered terminology, such as replacing the term “castration-resistant prostate cancer” with “androgen deprivation-resistant prostate cancer,” to foster better understanding and improve patient experience. The episode concludes with a forward-looking discussion on clinical trials, the integration of new technologies like liquid biopsies, and the ongoing efforts to expand insurance coverage for biomarker testing. Dr. Oh emphasizes the critical role of collaboration, awareness, and education in advancing precision medicine and ensuring that patients benefit from the latest innovations. With Karan's thoughtful questions and Dr. Oh's expertise, this episode offers a comprehensive and accessible exploration of how precision medicine is reshaping the future of prostate cancer care. We hope you'll tune in to the series and share this important episode with others!

    Dr. William Oh on How Precision Medicine and Early Detection Transform Outcomes in Prostate Cancer Care

    Play Episode Listen Later Dec 10, 2024 41:38


    In part one of a two-part series on prostate cancer, the Precision Medicine Podcast addresses critical challenges as well as new advancements in prostate cancer, the second leading cause of cancer-related deaths in men. Host, Karan Cushman, is joined by Dr. William Oh, Director of Precision Medicine at Yale Cancer Center and Chair of the American Cancer Society National Prostate Cancer Roundtable. Together, they shed light on the complexities of prostate cancer and how early screening can address rising incidence rates and persistent disparities, particularly among African American men. Subscribe to get Part 2 delivered straight to your inbox.Prostate cancer currently affects one in eight men in the US, with African American men facing a one-in-six risk and 70% higher incidence rate than White men. These disparities extend to earlier onset and more aggressive disease presentations. Globally, the disease is the most frequently diagnosed cancer in 112 countries and a leading cause of cancer-related deaths in 48 countries. The incidence of prostate cancer has been rising steadily. There has been a 3% annual increase in cases and a 5% annual rise in advanced prostate cancer diagnoses since 2014. Throughout the series, Dr. Oh discusses the role precision medicine can play in addressing these trends by tailoring prevention, diagnosis and treatment strategies to individual patient profiles. Karan and Dr. Oh begin the conversation by highlighting critical advances in prostate cancer care, including the development of over a dozen FDA-approved drugs in recent decades. Listeners will learn of the systemic barriers that often prevent men from accessing these treatments, resulting in just half of men with advanced prostate cancer receiving standard-of-care therapies—a fact that underscores the need to improve access and equity in treatment. Dr. Oh chairs the American Cancer Society National Prostate Cancer Roundtable, which aims to address these gaps by uniting diverse stakeholders—from patient advocacy groups to scientific organizations—to improve outcomes through collaborative efforts. The discussion also explores the role of environmental and epigenetic factors in prostate cancer risk. Dr. Oh discusses how stress, socioeconomic disparities, and toxic exposures, such as those experienced by 9/11 first responders, may alter DNA and increase cancer risk. He compares these findings to the higher incidence of prostate cancer among African American men who live in environments that exacerbate health disparities. Dr. Oh emphasizes the importance of identifying and mitigating these risks to improve outcomes. Screening is a key topic throughout the conversation, and Dr. Oh discusses the challenges of early detection and the controversies surrounding PSA (prostate-specific antigen) screening. While current guidelines recommend baseline PSA testing for most men between the ages of 50 to 55, new evidence supports earlier screening for high-risk populations, particularly African American men who should begin testing between ages 40 and 45. This shift toward earlier detection is critical for addressing aggressive cancers before they progress to advanced stages. Dr. Oh goes on to explain the importance of genetic testing, which reveals up to 10% of advanced prostate cancer cases involve BRCA or other DNA repair mutations. Recognizing these mutations early can inform targeted treatments like PARP inhibitors, yet Dr. Oh notes that many patients are not tested, underscoring the need for better implementation of precision diagnostics. By linking genetic data to clinical outcomes, precision medicine can help tailor treatments to the unique needs of each patient. The episode concludes with a call to action for improved education and collaboration. Dr. Oh emphasizes the need for patients to discuss family history and risk factors with their doctors and for primary care physicians to prioritize early conversations about prostate health. He advocates for a comprehensive approach that combines education, technology and multidisciplinary care to close gaps in prostate cancer treatment and ensure that advances in precision medicine benefit all populations, especially those at highest risk. Stay tuned for Part 2 with Dr. Oh coming out in late December 2024.

    New Legislation Helps Deliver Appropriate Biomarker Testing to More Cancer Patients When and Where They Need It

    Play Episode Listen Later Sep 10, 2024 37:43


    New Legislation Helps Deliver Appropriate Biomarker Testing to More Cancer Patients When and Where They Need It Currently, there is a significant divide between the promise of precision medicine and how equitably new innovations are applied to each cancer patient's treatment journey. Our expert guests Hilary Gee Goeckner (Director of State and Local Campaigns for the American Cancer Society's Cancer Action Network), and Kristine Ashcraft (founder and President of YouScript, and member of ACS CAN task force) are actively working to close that gap. They are champions of the ASC CAN effort to pass legislation across the US to expand insurance coverage of evidence-based biomarker testing for cancer patients. In this episode of the Precision Medicine Podcast, they explain why it's so important.Because biomarker testing is a complex topic, host Karan Cushman kicks off the episode by asking our guests to define the different types and their respective benefits. Hilary begins by explaining genetic testing and how results offer a view into someone's risk for developing cancer. She continues through diagnostic biomarker testing which can help match patients with the right treatments. Kristine then introduces pharmacogenomic/pharmocogenetic testing which looks at the genetic variability of how patients respond to drugs. It's clear that testing offers a wide range of benefits and having biomarker test results upfront can support clinicians in making more precise treatment decisions as well as modifications to drug selections and dosing based on a patient's individual profile. But our guests remind us that many underserved patients are less likely to receive guideline-indicated biomarker testing for a variety of reasons. Tune in to the full episode for more!

    How Trevor Maxwell Learned to Man Up to Cancer on His Journey with Colorectal Cancer

    Play Episode Listen Later Jun 4, 2024 33:14


    Welcome to Part 2 of a two-part colorectal cancer (CRC) awareness series featuring guest Trevor Maxwell, Founder and CEO of Man Up to Cancer, a non-profit that inspires men to connect and avoid isolation during their cancer journeys. Trevor shares what he's learned since being diagnosed with stage 4 CRC six years ago, the darkness he faced from mental health struggles and how he ultimately decided to Man Up to Cancer himself.​Precision medicine (i.e. “personalized” medicine) is predicated on the idea that treating the whole person leads to better outcomes. Trevor's story is evidence as host Karan Cushman takes listeners through his journey with cancer beginning with the less-than-obvious signs that led to his diagnosis at age 41.As husband to his wife, Sarah, and father to two young daughters, Sage and Elsie, Trevor now realizes he has a lot to live for, but in the initial months after he was diagnosed he couldn't see beyond the devasting news. He says he felt like an outlier—as if all other men with cancer were somehow shouldering the burden without help while he struggled. He later realized that many, many men felt the same way he did, and they were less likely to be accessing support resources than women. Trevor says, “I just realized that something needed to be done for those guys like me who maybe don't want to participate in a co-ed environment, and maybe if we give them something, maybe if we build something for them where it's by men going through cancer, for men going through cancer, maybe they'll open up.” This realization led Trevor to launch Man Up to Cancer. He says, “People who isolate going through cancer have worse medical outcomes, number one, and worse problems with mental health.” He created his non-profit to address those issues head on.Trevor notes that treating the whole person, not just the cancer, can save lives, but men first need to learn to ask for help. This whole-person approach is very much in line with the idea behind precision medicine today in that understanding ourselves and how we operate can optimize our treatment paths. As Trevor says, “For me, mental health was just as important as my physical health going through this [colorectal cancer]. For so many others, it's the same.” If you're living with cancer or supporting someone through their journey with cancer, please tune in to Part 2 of our incredibly candid and insightful conversation with Trevor. Not only is he truly inspiring, but he underscores how cancer patients reaching out to their communities and asking for support can sometimes literally be a matter of life or death. And don't miss the other episodes in our CRC awareness series, which includes Part 1 with Trevor in which he discusses the critical need for better screening for CRC as well as our broader discussion with Dr. Douglas Flora, Executive Medical Director of Oncology Services at St. Elizabeth Healthcare and Editor-in-Chief of AI and Precision Oncology.Download the full transcript of the episode here (pdf).Like what you hear? Please spread the joy...Share the Precision Medicine Podcast with your friends Leave a review and subscribe in your favorite podcast app!Follow us on Twitter @PMPbyTrapeloFollow us on Linked In at TrapeloHealthInterested in sponsoring the Precision Medicine Podcast?Email our host Karan Cushman: kcushman@trapelohealth.com​Don't miss the next episode...

    Part 1. The Alarming Rise of Colorectal Cancer: Advocate Trevor Maxwell Explains Why Basic Screening Is Mission Critical

    Play Episode Listen Later May 2, 2024 37:55


    Today, 80% of adults younger than 60 are not being effectively screened for colorectal cancer. They now have a 50% greater chance of being diagnosed than they did in the 90s. Additionally, the rise of early-onset CRC—even in otherwise healthy young people in their 20s and 30s—is unprecedented. This marks the 60th episode of the Precision Medicine Podcast as host Karan Cushman begins a two-part series focused on colorectal cancer with Trevor Maxwell, Founder and CEO of Man Up to Cancer. Trevor was diagnosed with CRC at age 41 and attests that it feels like we are back in the early days of breast cancer in terms of building awareness around the criticality of basic screening, yet the statistics are startling. In this Part 1, Trevor helps us understand the facts and current trends behind the second-leading cause of death for both men and women in America today. Trevor says the numbers are alarming, noting a 1% to 3% increase in the young-onset cohort every year. The big question, he says, is “why?”. 

    From Access to AI: Cancer in America with Dr. Douglas Flora

    Play Episode Listen Later Mar 26, 2024 36:04


    In this episode of the Precision Medicine Podcast, host Karan Cushman does some time traveling with Dr. Douglas Flora through his lifetime journey with cancer. Dr. Flora is the Medical Director of Oncology Services at St. Elizabeth Healthcare and Editor-in-Chief AI in Precision Oncology, a peer-reviewed research journal dedicated to advancing artificial intelligence applications in clinical and precision oncology. Read the full summary and tune in here. And don't forget to subscribe at precisionmedicinepodcast.com to get the latest delivered straight to your in-box.

    Dr. Pranil Chandra and Dr. Luis Raez: Enabling Comprehensive Genomic Profiling in Lung Cancer

    Play Episode Listen Later May 10, 2023 46:13


    In this episode of the Precision Medicine Podcast, hosts Karan Cushman and Clynt Taylor welcome back Dr. Luis Raez, Medical Director and Chief Scientific Officer at Memorial Cancer Institute who is joined by Dr. Pranil Chandra, Chief Genomic Officer at PathGroup. Together, we discuss the key barriers to performing comprehensive genomic profiling in lung cancer; how collaboration between oncologists and pathologists can enable a more consistent approach; and the improvements that should be made to close the gaps between the available life-extending, targeted therapies on the market today and the lung cancer patients who need them. To read the full summary, download the transcript and subscribe to receive future episodes straight to your in-box visit Precision Medicine Podcast Episode #58. Special thanks to our partners at Janssen Biotech for their sponsorship of this episode. We encourage you to share this episode with others in your community.

    Dr. Debra Patt: Texas Oncology Has an “Easy Button” for Delivering Consistent Precision Oncology Care

    Play Episode Listen Later Dec 14, 2022 26:37


    To mark the beginning of Season 5 of the Precision Medicine Podcast, we are honored to welcome Dr. Debra Patt, Executive Vice President of Texas Oncology. As an oncologist and breast cancer specialist at one of the nation's largest community cancer practices, Dr. Patt is on the frontlines of oncology care every day. She joins us to discuss how Texas Oncology uses clinical decision-support technologies and health economics and health services research (HEOR) to deliver more consistent precision oncology care to patients at over 200 locations across Texas. Tune in and subscribe to get the latest episode delivered straight to your in-box.

    Do We Have the Will to Address Inequality in Precision Oncology? A Conversation with Dr. Karen Winkfield

    Play Episode Listen Later Jun 3, 2022 52:41


    In this episode, we are joined by Dr. Karen Winkfield, Executive Director of the Meharry-Vanderbilt Alliance, appointee to President Joe Biden's National Cancer Advisory Board, and co-host of the weekly podcast, 3 Black Docs, which is dedicated to educating the community about health and health disparities in an approachable and entertaining way.Dr. Winkfield's commitment to her calling was clear by the fact that she joins us during her vacation to discuss racial disparities in the healthcare system that prevent many Black patients from seeking and receiving appropriate care. She tells us that she didn't discover her calling early and, due to family and cultural barriers of her own, she almost didn't pursue it at all. In fact, it took the support of a dedicated high-school teacher and nine emotional years to finish her undergraduate degree in biochemistry to get her where she is today as a practicing radiation oncologist.Off the top we ask Dr. Winkfield what can be learned from greater participation of underrepresented groups in clinical trials or greater participation in the healthcare system. She notes that Black people are still dying of cancer at a much higher rate than the rest of the population, and while there are some biologic reasons, much of the cause is under-representation in cancer clinical trials. We point out her step-by-step plan to address this type of imbalance in the healthcare system, and we are reminded that this is nothing new as she has been working to help address it for decades. She says, "Okay, I laid out a plan, but there's been a plan out for ending cancer disparities for over 20 years." The unequal burden document that was essentially kind of written by the Institutes of Medicine. Congress actually was the one who said, "Hey, we need to kind of understand what's going on with this cancer disparities thing." The whole plan is outlined.​Part of what the challenge is now is, do we have the will, do we have the will to do what is needed? Yes, I mean, there are those of us who've been kind of yelling from the mountaintops for decades now that we need to do something different because people are dying.” She goes on to explain that balancing disparity isn't as easy as, say, offering translation services, because institutionalized racism runs so deep that it presents barriers at every step. For instance, she says that if you look at the Cancer Genome Atlas Program, which has over 11,000 primary cancer samples, only 25 of those specimens are from prostate cancers derived from Black men, despite the fact that Black men not only have a much greater risk of developing prostate cancer, probably twice as high as any other racial ethnic group, and they're two-and-a-half times as likely to die of prostate cancer. She says, in America, your wealth directly impacts your health. Your zip code impacts your outcome more than your genetic code. We naturally asked what role technology can play in eliminating healthcare disparities, and she says that without more representative patient samples, trials and access, precision medicine can never be precise.In fact, she believes precision medicine can actually deepen the divide if it is not used with precision in terms of the whole person.Where do they come from? What are barriers to them accessing precision medicine, such as transportation or even paying for parking? Dr. Winkfield is a strong proponent of navigators who help cancer patients overcome those institutional barriers to ensure that they have equal access to the promise of precision medicine. She says, “These are the things, the social determinants of health, if we can stop and just see the person in front of us and say, what is it that you need to help you along your cancer journey? That to me is being precise.”

    Dr. Stephen Kingsmore on Scaling Whole Genome Sequencing for Uncovering Genetic Defects in Infants

    Play Episode Listen Later Mar 29, 2022 38:20


    In episode 55 of the Precision Medicine Podcast, we welcome Dr. Stephen Kingsmore, President and CEO of the Rady Children's Institute for Genomic Medicine. Dr. Kingsmore joins us to discuss the extraordinary role whole genome sequencing is playing in prolonging and improving the life of critically ill newborns.Read the full summary and tune in here!

    Leading Thoracic Oncologist, Dr. Christian Rolfo, Explains How Liquid Biopsies Are Advancing Precision Medicine

    Play Episode Listen Later Feb 16, 2022 30:49


    Dr. Christian Rolfo, President of the International Society of Liquid Biopsy and Associate Director for Clinical Research at the Center of Thoracic Oncology at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai in New York City, joins us to explain the unique role liquid biopsies are playing in the diagnosis and treatment of cancer.Read the full summary, subscribe and tune in here.Learn more about our lead sponsor Trapelo Health here.

    LUNGevity Leaders Discuss Their Commitment to Educating Lung Cancer Patients About the Importance of Biomarker Testing

    Play Episode Listen Later Jan 11, 2022 40:13


    In this Precision Medicine Podcast episode, we are joined by Dr. Belinda King-Kallimanis, Director of Patient-Focused Research at LUNGevity—an organization that brings together research, education and support services for patients and caregivers in the lung cancer community—and Nichelle Stigger, LUNGevity board member and lung cancer survivor. They sat down with us to discuss everything from the importance of patient-friendly language in lung cancer to discrepancies in access to biomarker testing and what LUNGevity is doing to improve the status quo. Read the full summary and listen here.

    Then and Now: The Progress of Precision Medicine Diagnostics with Hannah Mamuszka and Lena Chaihorsky of Alva10

    Play Episode Listen Later Nov 19, 2021 34:53


    In celebration of the three-year anniversary of the Precision Medicine Podcast, we take a look back at how far precision diagnostics have come with the help of one of our first guests Hannah Mamuszka, Founder and CEO of Alva10, and her colleague Lena Chaihorsky. Both women are focused on resolving the knowledge gap between payers and diagnostic companies and moving diagnostics to the forefront of the precision medicine conversation.Read the full summary and tune in here!

    Author and Breast Cancer “Previvor” Ali Rogan on How Progress in Precision Medicine Empowers Patients to Make Informed Decisions

    Play Episode Listen Later Oct 1, 2021 40:01


    In this episode, in honor of Breast Cancer Awareness Month, we speak with Ali Rogin, author of Beat Breast Cancer Like a Boss and award-winning producer of PBS NewsHour. Ali is what is commonly known as a breast cancer previvor, someone who knows they have a mutation that may lead to cancer and takes preventative steps to avoid a diagnosis. With the growth of genetic testing and precision medicine and the ability to isolate genes that can lead to cancer, more and more people may fall into the category of previvors. For instance, women that have the BRCA 1 or 2 mutation, as Rogin does, have a 70% chance of developing breast cancer by the age of 80. Rogin says progress in precision medicine has given these women options they would never have had before, enabling them to make proactive, informed decisions about their future health.

    Dr. Kashyap Patel Tackles Oncology Treatment Disparities and Brings Light to the Darkest Areas of Cancer Care

    Play Episode Listen Later Aug 27, 2021 39:32


    For our 50th episode, we welcome Dr. Kashyap Patel, medical oncologist and CEO of Carolina Blood and Cancer Center, current president of the Community Oncology Alliance (COA), and author of the book, Between Life and Death: From Despair to Hope. Dr. Patel explains the social determinants that can impact the quality of care and opportunity for precision medicine that patients—and specifically oncology patients—receive. For him, Covid-19 brought to light the impact that disparities in healthcare can have for all of us. He notes that one in three cancer deaths could be prevented if disparities didn't exist and that disparities result in 230B of excess expense. Read the full summary, listen and subscribe to the Precision Medicine Podcast here.

    Janine Morales, PhD On Applying Precision Medicine More Strategically With Molecular Testing

    Play Episode Listen Later Jul 28, 2021 32:21


    In this episode of the Precision Medicine Podcast, Janine Morales, PhD, Chief Scientific Officer at Trapelo Health takes us inside the complex world of evidence-based decision making in oncology. Specifically, she dives deeps into some of the nuances in the latest targeted therapy approvals and explains how having access to a real-time knowledge-base and a team of experts that curate current clinical evidence can empower physicians to make more appropriate decisions at the point of care. Read the full summary here and subscribe to join us in the advancement of precision medicine.

    Dr. Howard McLeod on Chasing the Fun and the Power of Collaboration in Precision Medicine

    Play Episode Listen Later Jun 17, 2021 40:36


    Dr. Howard McLeod is Medical Director for Precision Medicine at The Geriatric Oncology Consortium, a fellow of the American Society of Clinical Oncology and has worked on research projects with some of the most notable institutions around the world, including FDA, NIH, and NCI. We cover a lot of ground with Dr. McLeod in this podcast, including career advice, the advancement of precision medicine technology and the positive impact of COVID on telemedicine and clinical trials. Read the full summary and tune in to the audio here.

    Bill Bonello and Clynt Taylor Examine the Future of Precision Medicine and How to Provide Better Access to More Patients

    Play Episode Listen Later May 12, 2021 29:17


    Bill Bonello, president of NeoGenomics Informatics, and Clynt Taylor, president of Trapelo Health, discuss challenges in precision medicine and how evidence-based technologies can help deliver more appropriate, value-based care to more patients.As a subtext to the discussion is the recent acquisition of Trapelo Health, creator of clinical decision-making platform Trapelo, by NeoGenomics Informatics, provider of bioinformatics services. This acquisition is aimed at improving access to precision medicine testing and treatment. Read the full summary and learn more about Trapelo here.

    Dr. Caroline Carney and Clynt Taylor Discuss Managing the Total Cost of Care in Precision Medicine

    Play Episode Listen Later Apr 8, 2021 32:22


    In this notable episode, Dr. Caroline Carney, Chief Medical Officer at Magellan Health, and Clynt Taylor, CEO at Trapelo Health, join us to discuss how collaborative technologies can help payers more effectively manage the cost of precision oncology while delivering the best outcomes for patients. Read the full summary.

    Dr. F. Anthony Greco Explains How Precision Medicine Has Led to Better Treatments for Cancers of Unknown Origins

    Play Episode Listen Later Mar 30, 2021 33:29


    In this episode, Dr. F. Anthony Greco, medical oncologist at Tennessee Oncology, discusses the role that precision medicine has played in improving our diagnosis and treatment of cancer.

    Dr. Gabriel Bien-Willner Part 2: Helping Payers Adapt to the Paradigm Shift of Precision Medicine

    Play Episode Listen Later Feb 23, 2021 25:28


    In this Part 2 podcast featuring Dr. Gabriel A. Bien-Willner, Medical Director of the MolDX programat Palmetto GBA, we dive into the core challenges that payers face in navigating the explosion of precision medicine tests and treatments, and specifically how the prior authorization process can be streamlined by keeping payers updated on changes in coverage policy for new genes or CDx. Be sure to tune in to Part 1 with Dr. Bien-Willner who speaks about reshaping reimbursement policies for genetic and genomic testing.

    AbbVie’s Christopher Boone Integrates Real-World Data with Precision Medicine for Better Patient Outcomes

    Play Episode Listen Later Jan 22, 2021 36:14


    Christopher Boone, Vice President and Global Head of Health Economics & Outcomes Research at AbbVie, shares his thoughts on how using data to understand a patient’s real-world environment can expand the practice of Precision Medicine.

    Precision Medicine is Coming Faster Than You Think: Guests Rob Metcalf and Clynt Taylor

    Play Episode Listen Later Dec 9, 2020 26:30


    It is fitting that our first guests on Season 3 of the Precision Medicine Podcast are Rob Metcalf, CEO of Concert Genetics and Clynt Taylor, CEO of Trapelo Health who are both innovators in precision medicine technology. What we learn from them in this episode is that after 20 years of hearing about the “promise of precision medicine,” technology has reached a critical point where it can begin to accelerate that progress. Read the full summary, listen and learn more here.

    Dr. Luis Raez Discusses the Impact of Precision Medicine in Lung Cancer Treatment

    Play Episode Listen Later Nov 25, 2020 35:37


    In this episode, and in honor of lung cancer awareness month we had the opportunity to speak with Dr. Luis Raez, Medical Director and Chief of Hematology Oncology at Memorial Cancer Institute who focuses on treating lung cancer. Hear how the emergence of next-generation sequencing has changed his approach to lung cancer treatment, what notable discoveries in lung cancer have occurred over the last year, and how he sees COVID-19 impacting the treatment of cancer. Tune in to the full episode here.

    Dr. Luis Raez Discusses the Impact of Precision Medicine on Lung Cancer Treatment

    Play Episode Listen Later Nov 25, 2020 35:37


    In this 2-year anniversary episode, we had the opportunity to speak with Dr. Luis Raez, Medical Director and Chief of hematology oncology at Memorial Cancer Institute who focuses on treating lung cancer. Tune in to hear how the emergence of next-generation sequencing has changed his approach to lung cancer treatment, what notable discoveries in lung cancer have occurred over the last year, and how he thinks Covid-19 had impacted the treatment of cancer. Tune in to the full episode here.

    Dr. Gabriel Bien-Willner Part 1: Reshaping Reimbursement Policies for Genetic and Genomic Testing

    Play Episode Listen Later Oct 29, 2020 20:36


    In the first of a two-part podcast, Gabriel A. Bien-Willner MD, PhD, FCAP, Medical Director at MolDX, and Chief Medical Officer at Palmetto GBA shares how he has helped implement payer controls and coverage and set policies for affiliated Medicare Administrative Contractors in 28 states. In the past, payers have had to navigate the growing field of precision medicine without the benefit of expertise, so their only guidance came from the NCCN or consultations with other experts in the field. Today, under his direction, Palmetto GBA is able to base its policies on evidentiary reviews, and he believes this form of evidence-based decision-making should be an industrywide standard.

    Breast Cancer Specialist Dr. Mark Moasser Discusses Overcoming Barriers to Clinical Trial Access

    Play Episode Listen Later Sep 3, 2020 24:26


    Dr. Mark Moasser, a physician-scientist and breast cancer specialist at the University of California, San Francisco discusses his research focus on the HER2 oncogene, the latest trial findings and the importance of improving patient access to clinical trials. At Trapelo, connecting oncologists with patient-appropriate clinical trials is a major part of our mission, so we were grateful for the opportunity to talk to Dr. Moasser and learn more about his thoughts on this matter. Tune in to the full episode to learn more about his current research and perspective on the future of precision medicine.

    Lori Brisbin Explains How Trapelo Helps Keep Texas Oncology Ahead of the Precision Medicine Curve

    Play Episode Listen Later Aug 4, 2020 15:42


    In this episode, Clynt Taylor, CEO at Trapelo Health, talks with Lori Brisbin, Vice President of Precision Medicine at Texas Oncology, one of the largest practices in the United States. The discussion centers on how this expansive network of oncologists is leveraging the web-based Trapelo™ platform to provide evidence-based decision support to its physicians and bring precision medicine to the forefront of patient care

    Robin Toft on the Life Science Industry’s Talent Crisis, Advancement for Women, and Why It’s Critical for CEO’s to Focus on Diversity

    Play Episode Listen Later Jul 1, 2020 19:24


    On this Precision Medicine Podcast, author and CEO of the Toft Group (a ZRG company), Robin Toft, joins us to discuss her new book, We Can, and share her thoughts on the need for more women and greater diversity in the C-suite and the boardroom within the life science industry. Read the full summary here. 

    Dr. Roy Smythe Explains the Importance of Protein Expression in Practicing Precision Medicine

    Play Episode Listen Later May 27, 2020


    Roy Smythe, M.D, explains why proteins are more useful than genes for understanding the human body and creating precision medicines to heal it. Dr. Smythe is CEO of SomaLogic, a leading-edge, biotechnology company headquartered in Boulder, Colorado. The company scans human proteins to gain insights into the past, current, and future health of patients, making it a promising new technology for precision medicine outcomes. Tune in here for the full summary and more :https://www.trapelohealth.com/proteins-in-precision-medicine

    ROS1Ders: Lung Cancer Patients Turned Precision Medicine Advocates

    Play Episode Listen Later Apr 29, 2020


    In this Precision Medicine Podcast episode, we met with lung cancer patients Lisa Goldman and Tori Tomalia to discuss their organization, the ROS1ders, which they created to advocate and support those with ROS1-positive cancer—a group that represents just 2% of lung cancer patients. We were fascinated by how two women with no medical background could form a highly respected and resourceful group for those with this rare type of cancer. The women told us that when they and a mutual friend Janet were diagnosed with ROS1-positive lung cancer, they came together to learn more about precision medicine treatment options by reaching out to one of their doctors with questions. What they learned is that there wasn’t much information to be found, and, as the doctor said, they would need to bring together a critical mass of ROS1-positive lung cancer patients to enable better cancer models and the needle on research. That’s exactly what these heroic women did.

    Dr. John Quackenbush on Embracing Biological Complexity to Realize the Potential of Precision Medicine

    Play Episode Listen Later Mar 28, 2020


    In our second podcast with Dr. John Quackenbush, Chair of the Department of Biostatistics at Harvard University's T.H. Chan School of Public Health, we delved deeper into his approach to understanding cancer by studying entire gene networks rather than simple mutations. Read the full summary here, subscribe and learn more about our lead sponsor Trapelo Health.

    Dr. Arturo Loaiza-Bonilla: The Impact of Precision Medicine on Gastrointestinal Disease

    Play Episode Listen Later Mar 4, 2020


    In this episode of The Precision Medicine Podcast, we speak with Dr. Arturo Loaiza-Bonilla, Chief Medical Officer and Director of Research for the Cancer Treatment Centers of America in Philadelphia, about how precision medicine is changing the treatment of GI cancers. Learn about the personal experiences that inspired his medical career focus and the hidden talent that nearly stole him away.

    Precision Medicine is Here: Dr. Barbara Fortini Helps Prepare a New Generation of Scientists to Apply It

    Play Episode Listen Later Feb 14, 2020


    In this episode 32 of the Precision Medicine Podcast sponsored by Trapelo, we talk extensively with Barbara Fortini, PhD, the Program Director for the Master of Science in Human Genetics and Genomic Data Analytics program at the Keck Graduate Institute about what students of biology and genetics need to know today versus what they needed to know a decade ago, and how she sees those skills being applied in a clinical setting. Read the full summary, download the transcript and tune in here. Learn about our sponsor Trapelo here.

    Dr. Adam Brufsky shares the newest research from the San Antonio Breast Cancer Symposium

    Play Episode Listen Later Jan 27, 2020


    Dr. Adam Brufsky, Medical Director for the Women’s Cancer Program at the UPMC Hillman Cancer Center, shares the newest findings from the San Antonio Breast Cancer Symposium (SABCS) and discusses the important role of precision medicine in breast cancer care. Tune in and #Subscribe here https://bit.ly/2sT9y8r #PrecisionMedicinePodcast #SABC19  

    Dr. John Quackenbush: Using Massive Data to Approach Precision Medicine Beyond Simple Mutations

    Play Episode Listen Later Jan 9, 2020


    In this first episode of season two of the Precision Medicine Podcast, Dr. John Quackenbush discusses his approach to understanding what makes cancer cancer by studying entire gene networks rather than simple mutations. Dr. Quackenbush is Chair of the Department of Biostatistics at Harvard University's T.H. Chan School of Public Health and one of the first people to have worked on the Human Genome Project. Read our full summary and tune in to the episode here.

    Dr. Selin Kurnaz of Massive Bio Explains the Need to Operationalize Patient Support in Precision Cancer Care

    Play Episode Listen Later Dec 19, 2019


    In this episode, we speak with Dr. Selin Kurnaz, CEO and cofounder of Massive Bio, who led a panel at the Precision Medicine Leadership Summit in Philadelphia. The panel discussion, Precision Medicine Clinical Trials and Novel Designs: Levering Data, ‘Omics’, AI and Policy focused on the importance of increasing patient accessibility to clinical trials, an issue that drove Dr. Kurnaz to cofound her company. Read more in our full summary and tune in to the episode here.

    Advancing Precision Medicine by Breaking Down Information Silos with Entrepreneur Kristine Ashcraft

    Play Episode Listen Later Nov 19, 2019


    In this episode, we talk with Kristine Ashcraft, founder and CEO of YouScript, a platform that synthesizes all evidence impacting drug response, including pharmacogenetic testing, to support doctors and pharmacists in making faster, more proactive decisions at the point of care. For a summary and transcript visit https://bit.ly/2O5Fpuj

    Expanding the Reach of Precision Medicine

    Play Episode Listen Later Nov 7, 2019


    Dr. Bruce Johnson, Chief Clinical Research Officer from the Dana Farber Cancer Institute, joins us to discuss how recent advances in treating rare cancers can help drive the understanding and expansion of precision medicine.  

    Can Precision Medicine Be a Win-Win for All Stakeholders?

    Play Episode Listen Later Oct 24, 2019


    To celebrate our upcoming anniversary, we're going back to where the Precision Medicine Podcast made its debut nearly one year ago. Dr. Edward Abrahams is President of the Personalized Medicine Coalition (PMC) and host of the 15th Annual Personalized Medicine Conference coming up on November 13 at Harvard Medical School. In this episode, we discuss the evolution of precision medicine and the value it can bring to all stakeholders, including innovators, scientists, patients, providers, and payers. If you are a regular listener we've heard over and over about the challenges associated with convincing everyone—and most notably payers—of the value of precision medicine. So, we are excited to share Dr. Abrahams’ and the PMC’s vision for communicating it as a win-win for all stakeholders.

    Dr. Erica Stringer-Reasor shares her expertise on precision medicine advancements in breast cancer

    Play Episode Listen Later Oct 8, 2019


    In honor of breast cancer awareness month, Dr. Erica Stringer-Reasor joins us to discuss how breast cancer has led the way in the adoption of precision medicine. Dr. Stringer-Reasor is an expert in the field of breast cancer, a fast-rising star in cancer research and Assistant Professor of Hematology Oncology at the University of Alabama, Birmingham.

    Nigel Russell: Creating a Community of Precision Medicine Leaders by Leveraging the Media to Drive Innovation 

    Play Episode Listen Later Sep 26, 2019


    In this podcast, Nigel Russell, Founder and Co-president of the Journal of Precision Medicine and host of the Precision Medicine Leadership Summit, joins us to talk about how his team communicates the importance and challenges of Precision Medicine to a broad and sometimes under-informed readership.

    Dr. Jack West of City of Hope Shares Why Time-Strapped Community Oncologists Aren't Applying Precision Medicine

    Play Episode Listen Later Sep 9, 2019


    In Part Two of our two-part interview with Dr. Jack West, Associate Clinical Professor at the City of Hope Comprehensive Cancer Center, we discuss the differences between how community oncologists are applying—or in many cases not applying—precision medicine as opposed to how it is applied by academic oncologists.

    Randall Broad on the Importance of Two-Way Communication Between Cancer Patients and Their Physicians

    Play Episode Listen Later Aug 23, 2019


    Ten-year cancer survivor and patient advocate Randall Broad, shares his personal story with stage III non-small cell lung cancer and how that experience made him acutely aware of the need for improved communication between patients and physicians in an effort to facilitate mutual understanding and better outcomes. Listen here. ​

    Dr. Michael Kolodziej on 3 Trends That Can Change Cancer Care Forever: Part 2

    Play Episode Listen Later Aug 13, 2019


    Dr. Michael Kolodziej is CIO at ADVI Health and a pioneer in developing value-based reimbursement models for cancer care. Having seen him present his talk, “The Healthcare Landscape of 2025: 3 Trends That Can Change Cancer Care Forever,” at a Florida Association of Clinical Oncology (FLASCO) event, we were anxious to dive deeper into the trends here on the Precision Medicine Podcast. In this part two podcast, he talks about payer reform and alternative payer models in cancer care today.

    Chet Burrell on How Trapelo Will Help Payers Manage the Growth of Precision Oncology to Improve Member Care and Lower Costs

    Play Episode Listen Later Jul 26, 2019


    Mr. Chet Burrell, former president and CEO of Care First Blue Cross Blue Shield and Executive Chairman of the Intervention Insights Board of Directors, discusses the challenges payers face in managing the growth of precision medicine for cancer care and why he's championing Trapelo's precision diagnostic platform as the first collaborative technology solution.

    Dr. Jack West of City of Hope Shares Why Time-Strapped Community Oncologists Aren't Applying Precision Medicine

    Play Episode Listen Later Jul 11, 2019


    In this first episode with Dr. Jack West, we discuss the state of precision oncology and the challenges providers face when it comes to performing the right molecular tests to appropriately prescribe targeted therapies. Leave a review and subscribe here.

    Dr. Jack West of City of Hope Shares Why Time-Strapped Community Oncologists Aren't Applying Precision Medicine

    Play Episode Listen Later Jul 11, 2019


    In this first episode with Dr. Jack West, we discuss the state of precision oncologyand the challenges providers face when it comes to performing the right molecular tests to appropriately prescribe targeted therapies. Leave a review and subscribe here.

    Claim Precision Medicine Podcast

    In order to claim this podcast we'll send an email to with a verification link. Simply click the link and you will be able to edit tags, request a refresh, and other features to take control of your podcast page!

    Claim Cancel